Zolbetuximab with gemcitabine plus nab-paclitaxel (GN) in first-line treatment of Claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study

被引：1

作者：

Park, W. ^{[1
]}

O'Reilly, E. M. ^{[2
]}

Li, C-P. ^{[3
,4
]}

Oh, D-Y. ^{[5
]}

Garcia-Carbonero, R. ^{[6
]}

Roth, G. ^{[7
]}

Nakajima, T. ^{[8
]}

Moran, D. ^{[9
]}

Yang, J. ^{[10
]}

Li, R. ^{[11
]}

Kunieda, F. ^{[12
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA

[2] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Med Dept, New York, NY USA

[3] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Div Clin Skills Training, Dept Med,Dept Med Educ, Taipei, Taiwan

[4] Taipei Vet Gen Hosp, Therapeut & Res Ctr Pancreat Canc, Taipei, Taiwan

[5] Seoul Natl Univ Hosp, Internal Med Dept, Seoul, South Korea

[6] Univ Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain

[7] Univ Grenoble Alpes, CHU Grenoble Alpes, Hepatogastroenterol & Digest Oncol Dept, Inst Adv Biosci, St Martin Dheres, France

[8] Astellas Pharma Global Dev, Med Dept, Northbrook, IL USA

[9] Astellas Pharma USA, Clin Pharmacol & Exploratory Dev Dept, Northbrook, IL USA

[10] Astellas Pharma USA, Early Dev, Northbrook, IL USA

[11] Astellas Pharma Global Dev Inc, Data Sci, Northbrook, IL USA

[12] Astellas Pharma Inc, Develoment, Chuo Ku, Tokyo, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2024.08.1595

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1532TiP

引用

页码：S934 / S934

页数：1